



Julie Cherrington Appointed Chair of Xenome's Board of Directors Experienced Industry Executive to Lead in Critical Phase

BRISBANE, Australia, 11 January 2012: Biopharmaceutical company Xenome Limited announced the appointment of independent Board Member Dr Julie Cherrington as Chair of its Board. This follows Xenome's recently announced A\$8 million financing to support the ongoing development of Xen2174 in acute post surgical pain.

Dr Cherrington is the President and CEO of Pathway Therapeutics, Inc. She has held numerous senior leadership positions at prominent biotechnology companies such as SUGEN, Gilead Sciences and Phenomix Corporation. She joined the Xenome Board as an independent, Non-Executive Director in August 2009. She was previously on the boards of Progen Pharmaceuticals and ChemGenex Pharmaceuticals.

"Julie's extensive experience in critical phases of drug development will prove pivotal as we advance our proof of concept clinical program for Xen2174 in acute post surgical pain" said Executive Director, Michael Aldridge.

Dr Cherrington added, "I am excited by the potential of Xenome's novel non-opiate pain medication and pleased to contribute my experience and expertise as leader of its Board."

Xenome is developing Xen2174, a new therapeutic being developed for the management of moderate to severe pain. Xen2174 is a proprietary 13-amino acid synthetic peptide, which has shown promise as a non-opiate pain therapeutic when administered intrathecally.

About Xenome:

Xenome is a biopharmaceutical company focused on the discovery and development of peptide-based therapeutics. The Company's lead molecule, Xen2174, is a novel conopeptide analogue being developed for the management of moderate to severe pain. Xen2174 is a highly selective and non-competitive inhibitor of norepinephrine transporter (NET), a validated target for the management of pain.

Contact information:

Company:

Michael Aldridge

Executive Director

E: enquiries@xenome.com

W: www.xenome.com

Intentionally Blank